outstanding results compared with PAP test

Hi All
Bit quiet around here.
Because some investors don't know how well this device compares with the Pap test I'd thought I'd round up and review a bit of recent data,
keep in mind that there is some old data out there which shows the device has moderate detection rates ( in old trials completed prior to 2018 ).

The new data (outlined below) is from the upgraded Truscreen device, it has better parts, increased performance, and new AI software, it was released in December 2017.

So just thought I'd remind some of you and inform any investors new to TRU just how good the Truscreen test rates;
(remember also the cost of conducting PAP test is significantly more than Truscreen)

best regards to all
fp

Outstanding Results from TruScreen Indian Screening Trial

Highlights

• TruScreen’s real-time cervical cancer screening device has demonstrated improved sensitivity and specificity targeting pre-cancerous and cancerous cervical cells compared to a Pap test in a trial in India
• India is a significant potential market for TruScreen
• The national All India Institute of Medical Sciences (AIIMS) conducted the trial involving 645 women at a tertiary referral centre in New Delhi and at a comprehensive rural health services centre at Ballabgarh, Haryana

Auckland - Real-time cervical cancer screening technology company TruScreen (NZX: TRU) or (“the Company”) says results from its first cervical cancer screening trial in India confirm that the TruScreen device is an effective, viable and non-invasive method of detecting cervical intra-epithelial neoplasia (CIN).

The trial, conducted by the All India Institute of Medical Sciences (AIIMS) in New Delhi and the town of Ballabgarh over the period January 2018 to February 2019, screened 645 women for cervical cancer.

All women in the trial underwent screening for CIN, using TruScreen’s opto-electrical device and a Pap test. The sensitivity of the TruScreen device to detect CIN was 81.82%compared to 72.73% by the Pap test. The specificity of the TruScreen device was 82.87% compared to 79.81% by the Pap test.

Sensitivity and specificity are measures of a screening test’s ability to correctly identify disease. A high sensitivity results in fewer false negatives, and a high specificity results in fewer false positives in the screening process.


Then another trial........
SICHUAN PROVINCE TRIAL CONFIRMS TRUSCREEN TECHNOLOGY

This second preliminary trial results were presented by the lead investigator of the COGA project in Sichuan Province at COGA’s annual congress in September 2020. The trial covered 14 hospitals and 1,243 patients in the data analysis.
Truscreen’s results from this second phase, outlined below, were better or on parity than tests for HPV (Human Papillomavirus DNA Test) and LBC (Liquid-cased Cytology). These results confirm Hunan Province results announced in 2019.

Truscreen had a Sensitivity of 86% (HPV 94%, LBC 73%)
Truscreen had a Specificity of 74% (HPV 18%, LBC 53%)
Truscreen had a PPV 52% (HPV 27%, LBC 34%)
Truscreen had a NPV 94% (HPV 89%, LBC 86%).

Sensitivity measures correctly a positive result for patients who have the condition that is being tested for (also known as the “true positive” rate). A test that’s highly sensitive will indicate patients who have the disease.

Specificity measures correctly a negative result for people who don’t have the condition that is’ being tested for (also known as the “true negative” rate). A high-specificity test will correctly rule out patients who do not have the disease.

PPV - Positive Predictive Value is the probability that subjects with a positive screening test truly have the disease.

NPV - Negative Predictive Value is the probability that subjects with a negative screening test truly don't have the disease

----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Formal Publication will occur when the full 20,000 patients have been screened. Interim results from the Sichuan and Hunan clinical evaluation validate the strong potential for the TruScreen cervical cancer screening device to improve women’s health in China.